卵巢癌铂类化疗耐药的分子机制研究进展
Advances in molecular mechanisms of resistance to platinum chemotherapy in ovarian cancer
刘影 1梁义娟 2解丹 2闫丽伟 2刘璐 2王伟明2
作者信息
- 1. 河北大学附属医院妇科, 河北 保定 071000;河北大学临床医学院, 河北 保定 071000
- 2. 河北大学附属医院妇科, 河北 保定 071000
- 折叠
摘要
铂类药物是卵巢癌最有效的化疗药物之一,虽然铂类化疗的初始反应高达80%,但耐药性很常见.在大多数晚期患者中,最终复发和死亡是由获得性耐药所引起.卵巢癌化疗耐药性是影响其治疗效果的重大障碍,然而化疗耐药其病因不清、机制复杂,是临床及科研中急需解决的难点和热点.因此,卵巢癌耐药机制的研究将为卵巢癌化疗的探索及研发提供依据.现关于卵巢癌铂类耐药的分子机制进行综述.
Abstract
Platinum drugs are one of the most effective chemotherapy drugs for ovarian cancer,and although the initial response to platinum chemotherapy is as high as 80%,resistance is common.In most advanced patients,eventual relapse and death are caused by acquired resistance.Chemotherapy resistance of ovarian cancer is a major obstacle affecting its therapeutic effect.However,the cause of chemotherapy resistance is unclear and the mechanism is complex,which is a difficult and hot point in clinical and scientific research.Therefore,the study of drug resistance mechanism of ovarian cancer will provide a basis for the exploration and development of chem-otherapy for ovarian cancer.This article reviews the molecular mechanism of platinum resistance in ovarian cancer.
关键词
卵巢癌/铂类化疗耐药性/分子机制Key words
ovarian cancer/platinum chemotherapy resistance/molecular mechanism引用本文复制引用
基金项目
河北省政府项目(ZF2024218)
河北大学医学学科培育项目(2020B06)
出版年
2024
NETL
NSTL
万方数据